Symbol
| PAX2
| contributors: mct/npt/pgu - updated : 15-06-2015
|
HGNC name
| paired box 2
|
HGNC id
| 8616
|
Other morbid association(s)
|
Type | Gene Modification | Chromosome rearrangement | Protein expression | Protein Function
|
---|
tumoral
|  
|  
|  
|  
|
in breast cancer | constitutional
| mosaic
|  
|  
|  
|
germinal mosaicism | constitutional
|  
|  
| --low
|  
|
dysregulated and leading to diseases in cases of haploinsufficiency(see ONCRV) or persistent expression (see DDS) | tumoral
|  
|  
|  
|  
|
activated by oestrogen and tamoxifen in endometrial carcinomas | tumoral
|  
|  
|  
| loss of function
|
reactivation of PAX2 frequently observed in clear cell renal cell carcinoma (ccRCC), a tumor type characterized by loss of von Hippel-Lindau (VHL) tumor suppressor function | tumoral
|  
|  
|  
| gain of function
|
in low-grade ovarian serous carcinoma | tumoral
|  
|  
| --over
|  
|
in human colon cancers ( | |
Variant & Polymorphism
|
| |
Candidate gene
| strong candidate gene for cases in which human patients have optic disc coloboma not associated with renal dysplasia |
Marker
| biomarker for a more aggressive medulloblastoma phenotype |
Therapy target
|
System | Type | Disorder | Pubmed |
cancer | reproductive | prostate | |
therapeutic target for prostate cancer treatment | tumor | kidney | | |
appropriate target for the development of novel therapies for PKD1 | cancer | urinary | | |
potential therapeutic gene target in renal cancer and adjunctive PAX2 knockdown may enhance the efficacy of other chemotherapeutic agents | cancer | brain | | |
may represent a novel therapeutic target in medulloblastoma |
| |
| homozygous Pax2 knockout mice fail to develop kidneys, ureters and genital tracts | |
heterozygous mice for Hnf1b and Pax2 null alleles display phenotypes similar to severe congenital anomalies of the kidney and the urinary tract (CAKUT), including strong hypoplasia of the kidneys, caudal ectopic aborted ureter buds, duplex kidneys, megaureters and hydronephrosis |